Selective elimination of erosive cells
AssigneeNovo Nordisk A/S
InventorsKalle Soederstroem, Elisabeth Douglas Galsgaard
Life of this patent
Estimating the term…
Abstract
The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.
Claims13
A method for treating a subject having osteoporosis and bone erosion, the method comprising administering an anti-NKG2A antibody, or an antigen binding fragment thereof to said subject, wherein said antibody blocks inhibitory signaling by CD94-NKG2A receptors and is a non-depleting antibody, and wherein said antibody has a heavy chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO:
- 2 and a light chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO:
- 3, or wherein said antibody has a heavy chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO:
- 4 and a light chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO:
- 5.
A method for treating osteoporosis comprising administering an anti-NKG-2A antibody, or an antigen binding fragment thereof, to a subject in need thereof, wherein said antibody has a heavy chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO:
- 2 and a light chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO:
- 3, or wherein said antibody has a heavy chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO:
- 4 and a light chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO:
- 5.
Dependencies are inferred from the claim text.